Evidence map›Paper›PMID 30449719›Full record

Trial reportGynecologic oncology2019

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.

Antonio González Martín, Amit M Oza, Andrew C Embleton, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Monique A Bertrand, Philip Beale, Andrés Cervantes and 6 more

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 6 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 6 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023
    Pooled it
  3. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Guideline
  5. Guideline
  6. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2020
    Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Observational
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.Current treatment options in oncology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 8 countries.

Antonio González MartínMD Anderson Cancer Center Spain, Madrid, Spain. Electronic address: agonzalezm@seom.org.
Amit M OzaPrincess Margaret Cancer Centre, University Health Network Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada. Electronic address: Amit.Oza@uhn.ca.
Andrew C EmbletonMedical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK. Electronic address: a.embleton@ucl.ac.uk.
Jacobus PfistererGynecologic Oncology Center, Herzog-Friedrich-Str. 21, 24103 Kiel, Germany. Electronic address: jacobus.pfisterer@googlemail.com.
Jonathan A LedermannUCL Cancer Institute, 90 Tottenham Court Road, London W1T 4TJ, UK. Electronic address: j.ledermann@ucl.ac.uk.
Eric Pujade-LauraineHôpital Hôtel-Dieu, Assistance Publique - Hôpitaux de Paris, 1, Parvis Notre-Dame - Place Jean-Paul II, 75181 Paris CEDEX 04, France. Electronic address: epujade@arcagy.org.
Gunnar KristensenDepartment of Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Radiumhospital, Oslo University Hospital, PO Box 4950, Nydalen, N-0424 Oslo, Norway. Electronic address: gunnar.b.kristensen@gmail.com.
Monique A BertrandWestern University and London Health Sciences Centre, 800 Commissioners Road East, PO Box 5010, Stn B, London, ON N6A 5W9, Canada. Electronic address: monique.bertrand@lhsc.on.ca.
Philip BealeUniversity of Sydney and Royal Prince Alfred Hospital, Level 6, Gloucester House, RPAH, Missenden Road, Camperdown, NSW 2050, Australia. Electronic address: Philip.Beale@health.nsw.gov.au.
Andrés CervantesCIBERONC, Biomedical Research Institute INCLIVA, University of Valencia and Hospital Clínico de Valencia, Servicio de Hematología y Oncología Médica, Av. Blasco Ibáñez 17, 46010, Valencia, Spain. Electronic address: andres.cervantes@uv.es.
Emma KentMedical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK. Electronic address: Emma.Kent@nice.org.uk.
Richard S KaplanMedical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK. Electronic address: r.kaplan@ucl.ac.uk.
Mahesh K B ParmarMedical Research Council Clinical Trials Unit at University College London (UCL), 90 High Holborn, London WC1V 6LJ, UK. Electronic address: m.parmar@ucl.ac.uk.
Nana ScottoF. Hoffmann-La Roche Ltd, Building 1, Grenzacherstrasse 124, CH-4070 Basel, Switzerland. Electronic address: nana.scotto@roche.com.
Timothy J PerrenLeeds Institute for Cancer Medicine and Pathology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK. Electronic address: t.j.perren@leeds.ac.uk.
ICON7 investigators
MRC Clinical Trials Unit at UCL · GBAssistance Publique – Hôpitaux de Paris · FRCancer Research UK · GBHerzog Hospital · ILMD Anderson Cancer Center Madrid · ESOslo University Hospital · NORoche (Switzerland) · CHSt James's University Hospital · GBThe University of Sydney · AUUniversitat de València · ESUniversity Health Network · CAWestern University · CA

Funding

Cancer Research UK 17092Medical Research Council MC_U122861379Medical Research Council MC_UU_12023/20Medical Research Council MC_UU_12023/9
6 · The paper itself

Abstract

objectiveIn the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease.

methodsPatients with stage IIB-IV or high-risk (grade 3/clear-cell) stage I-IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5 mg/kg every 3 weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc exploratory analyses of subgroups defined by stage and extent of residual disease at diagnosis within the stage IIIB-IV population (European indication) was performed.

resultsThe PFS benefit from bevacizumab was seen consistently in all subgroups explored. The PFS hazard ratio was 0.77 (95% confidence interval [CI], 0.59-0.99) in 411 patients with stage IIIB-IV ovarian cancer with no visible residuum and 0.81 (95% CI, 0.69-0.95) in 749 patients with stage IIIB-IV disease and visible residuum. As in the ITT population, no OS difference was detected in any subgroup except the previously described 'high-risk' subgroup. Safety results in analyzed subgroups were consistent with the overall population.

conclusionsAdding bevacizumab to front-line chemotherapy improves PFS irrespective of stage/residual disease. In patients with stage III with >1 cm residuum, stage IV or inoperable disease, this translates into an OS benefit. No OS benefit or detriment was seen in other subgroups explored.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinFemaleHumansNeoplasm, ResidualNeoplasm StagingOvarian NeoplasmsPaclitaxelBevacizumabCarboplatinPaclitaxelBevacizumabCytoreductive surgeryOvarian cancerResidual disease

Identifiers

PMID30449719
PMCPMC6338677
OpenAlexW2901022488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.